The Biden administration is looking to avoid the same hiccups experienced during the rollout of new COVID-19 vaccines as it begins shifting coverage of coronavirus treatments to the private market.

Just as with Covid-19 vaccines this season, the antiviral – a combination of the drugs nirmatrelvir and ritonavir – will move from being available free to everyone through government purchases to a ...

The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to sell it on the commercial market later this year. A company spokesperson on Wednesday ...